RecruitingNCT06441578
A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
Studying Congenital thrombotic thrombocytopenic purpura
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Takeda
- Principal Investigator
- Study DirectorTakeda
- Intervention
- Recombinant ADAMTS13(drug)
- Enrollment
- 40 enrolled
- Eligibility
- All sexes
- Timeline
- 2024 – 2032
Study locations (1)
- Takeda selected site, Tokyo, Japan
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06441578 on ClinicalTrials.govOther trials for Congenital thrombotic thrombocytopenic purpura
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07513948Daratumumab in Immune-mediated Thrombotic Thrombocytopenic PurpuraFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- RECRUITINGNCT01257269Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)Insel Gruppe AG, University Hospital Bern
See all trials for Congenital thrombotic thrombocytopenic purpura →